Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT01928160
What this trial is testing

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)UnknownNCT04470076
What this trial is testing

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Who this might be right for
Non Small Cell Lung CancerSurgeryEGFR Activating Mutation+2 more
Fifth Affiliated Hospital, Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Study completedNCT01530334
What this trial is testing

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Who this might be right for
Lung Cancer
AstraZeneca 61
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Large-scale testing (Phase 3)Looking for participantsNCT07010419
What this trial is testing

Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

Who this might be right for
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc. 338
Testing effectiveness (Phase 2)Ended earlyNCT04512430
What this trial is testing

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Fundación GECP 4
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Not applicableTemporarily pausedNCT05421936
What this trial is testing

Osimertinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Carcinoma, Non-Small-Cell LungGenes, erbB-1
Sheba Medical Center 100
Not applicableStudy completedNCT03750175
What this trial is testing

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Who this might be right for
Colorectal Cancer MetastaticCirculating Tumor DNAKRAS Gene Mutation+3 more
Karen-Lise Garm Spindler 49
Testing effectiveness (Phase 2)UnknownNCT04592666
What this trial is testing

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Who this might be right for
Lung Cancer, Non-small CellEGFR T790MEGFR Gene Mutation
Fudan University 226
Not applicableNot Yet RecruitingNCT07701070
What this trial is testing

SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

Who this might be right for
Advanced Breast Cancer
AstraZeneca 3,000
Testing effectiveness (Phase 2)UnknownNCT03720873
What this trial is testing

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 90
Not applicableUnknownNCT04909073
What this trial is testing

Observational Study of Afatinib 30 mg Daily

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore 69
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Large-scale testing (Phase 3)UnknownNCT04058704
What this trial is testing

Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy

Who this might be right for
Non Small Cell Lung CancerBrain Metastases
Betta Pharmaceuticals Co., Ltd. 296
Testing effectiveness (Phase 2)UnknownNCT01843647
What this trial is testing

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Who this might be right for
Non-small-cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 100
Not applicableUnknownNCT03671538
What this trial is testing

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Lingyu Luo 62
Next Page